These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16842237)

  • 1. Chk1 inhibitors for novel cancer treatment.
    Tao ZF; Lin NH
    Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
    Xiao Z; Xue J; Sowin TJ; Zhang H
    Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
    Li Q; Zhu GD
    Curr Top Med Chem; 2002 Sep; 2(9):939-71. PubMed ID: 12171565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
    McNeely S; Beckmann R; Bence Lin AK
    Pharmacol Ther; 2014 Apr; 142(1):1-10. PubMed ID: 24140082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
    Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S
    Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.
    Evison BJ; Pastuovic M; Bilardi RA; Forrest RA; Pumuye PP; Sleebs BE; Watson KG; Phillips DR; Cutts SM
    Biochem Pharmacol; 2011 Dec; 82(11):1604-18. PubMed ID: 21889927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
    J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
    Zenvirt S; Kravchenko-Balasha N; Levitzki A
    Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
    Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
    King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
    Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.
    Ma CX; Janetka JW; Piwnica-Worms H
    Trends Mol Med; 2011 Feb; 17(2):88-96. PubMed ID: 21087899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
    Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.
    Bucher N; Britten CD
    Br J Cancer; 2008 Feb; 98(3):523-8. PubMed ID: 18231106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells.
    Koniaras K; Cuddihy AR; Christopoulos H; Hogg A; O'Connell MJ
    Oncogene; 2001 Nov; 20(51):7453-63. PubMed ID: 11709716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5‑FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53‑mutated colon cancer cells.
    Akasaka T; Tsujii M; Kondo J; Hayashi Y; Ying J; Lu Y; Kato M; Yamada T; Yamamoto S; Inoue T; Tsujii Y; Maekawa A; Fujinaga T; Shiraishi E; Hiyama S; Inoue T; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
    Int J Oncol; 2015 Jan; 46(1):63-70. PubMed ID: 25310623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.
    Del Nagro CJ; Choi J; Xiao Y; Rangell L; Mohan S; Pandita A; Zha J; Jackson PK; O'Brien T
    Cell Cycle; 2014; 13(2):303-14. PubMed ID: 24247149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.